These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7567127)

  • 21. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation.
    Edenborough FP; Stone HR; Kelly SJ; Zadik P; Doherty CJ; Govan JR
    J Cyst Fibros; 2004 Mar; 3(1):37-44. PubMed ID: 15463885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.
    Döring G; Jansen S; Noll H; Grupp H; Frank F; Botzenhart K; Magdorf K; Wahn U
    Pediatr Pulmonol; 1996 Feb; 21(2):90-100. PubMed ID: 8882212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Nocardia farcinica infection in a patient with cystic fibrosis].
    Beucher J; Belleguic C; Brinchault G; Deneuville E; Donnio PY; Roussey M
    Rev Mal Respir; 2010; 27(1):76-9. PubMed ID: 20146956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyagglutinable Pseudomonas aeruginosa from cystic fibrosis patients. A survey.
    Ojeniyi B
    APMIS Suppl; 1994; 46():1-44. PubMed ID: 7811529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
    Nazik H; Ongen B; Erturan Z; Salcioğlu M
    Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
    Hayes D; Kanga JF; Anstead MI; Kuhn RJ
    Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR; Pressler T; Hoiby N; Johansen HK
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic & genotypic variants of Pseudomonas aeruginosa isolated from children with cystic fibrosis in India.
    Agarwal G; Kapil A; Kabra SK; Chandra R; Das B; Diwedi SN
    Indian J Med Res; 2002 Aug; 116():73-81. PubMed ID: 12592994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis.
    da Silva Filho LV; Tateno AF; Martins KM; Azzuz Chernishev AC; Garcia Dde O; Haug M; Meisner C; Rodrigues JC; Döring G
    Pediatr Pulmonol; 2007 Oct; 42(10):938-44. PubMed ID: 17722007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
    Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
    J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.